The Expression of circANKRD36 as a New Biomarker of Diabetic Nephropathy

Status Not yet recruiting

Clinical Trial Summary

1. To evaluate expression levels of circANKRD36 in the development and progression of DN. 2. To investigate correlation between expression levels of circANKRD36 and stages of DN. 3. To investigate correlation between expression levels of circANKRD36 and pro-inflammatory cytokine (TNF-α and IL-6) in T2DM patients with CKD.

Clinical Trial Description

Type 2 Diabetes Mellitus (T2DM) is one of the most common metabolic disorders that's become a global health burden affecting 463 million people worldwide according to the International Diabetes Federation (IDF). Diabetic nephropathy(DN) is one of the most common secondary complications of DM and is becoming a major cause of morbidity and mortality among diabetic patients . DN is a microvascular complication occurring in approximately 20-40% of patients with T2DM . DN has been described as a glomerular disorder with the following phases: glomerular hyperfiltration, incipient nephropathy, microalbuminuria, overt proteinuria and end-stage renal disorder. Microalbuminuria is the gold standard for the early diagnosis of DN. However, many studies have suggested that it is inadequate and has some drawbacks. Recent novel biomarkers have been accepted for early diagnosis and progression of DN in patients with T2DM . Renal cells are capable of synthesizing pro-inflammatory cytokines such as tumor necrotic factor-alpha (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6), these cytokines acting in a paracrine or autocrine manner that leading to the development and progression of several renal disorders .Circular RNAs are class of endogenous non coding RNAs and are associated with numerous diseases like T2DM. Circular ankyrin repeat domain 36 (circANKRD36) involved in T2DM and inflammation-associated pathways via interaction with miRNAs, including hsa-miR-3614-3p, hsa-miR-498, and hsa-miR-501-5p. The expression of circANKRD36 was upregulated in peripheral blood leucocytes and was correlated with chronic inflammation in T2DM. Therefore, circANKRD36 can be used as a potential biomarker for screening chronic inflammation in patients with T2DM. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05061459
Study type	Observational
Source	Assiut University
Contact	Marwa Magdy Hamed Mohamed, Assistant lecturer
Phone	01005745012
Email	marwamagdy@med.aun.edu.eg
Status	Not yet recruiting
Phase
Start date	October 2021
Completion date	November 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04562025` - Clinical Research of UC-MSCs in the Treatment of Diabetic Nephropathy	N/A
Not yet recruiting	`NCT03658317` - Renal Resisitive Index as an Indicator of the Progression of Diabetic Nephropathy	N/A
Recruiting	`NCT02501772` - The Evaluation of Effect of Sanyinjiao (SP6) Acupressure on Early Diabetic Nephropathy	N/A
Completed	`NCT02276196` - Effect of LIXIsenatide on the Renal System	Phase 4
Completed	`NCT02829177` - Microalbuminuria and Allopurinol in Type 1 Diabetes	Phase 4
Completed	`NCT02251067` - Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients	Phase 2
Completed	`NCT01440257` - A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria	Phase 2
Active, not recruiting	`NCT01273675` - An Investigation on the Effect of Candesartan on Early Diabetic Nephropathy	N/A
Terminated	`NCT01129557` - Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease	Phase 4
Completed	`NCT00317954` - Spironolactone in Diabetic Nephropathy	Phase 4
Active, not recruiting	`NCT02237352` - Mechanisms of Diabetic Nephropathy in Ecuador
Completed	`NCT01935167` - To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy	Phase 2
Recruiting	`NCT01673204` - Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy	Phase 4
Completed	`NCT01726816` - Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy	Phase 2
Recruiting	`NCT01458158` - Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease	N/A
Completed	`NCT01476501` - Vitamin D Supplementation in Diabetic Nephropathy	Phase 2
Completed	`NCT01447147` - A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy	Phase 2
Completed	`NCT01003236` - Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy	Phase 2
Completed	`NCT00535925` - Nephropathy In Type 2 Diabetes and Cardio-renal Events	Phase 4
Completed	`NCT00097955` - Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.